INH A21

Drug Profile

INH A21

Alternative Names: INH-A00021; INHA-21; Veronate

Latest Information Update: 21 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inhibitex
  • Class Immunoglobulins; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Staphylococcal infections; Nosocomial infections; Neonatal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neonatal infections; Nosocomial infections; Staphylococcal infections

Most Recent Events

  • 11 Jul 2006 Review of final results from a phase III clinical trial in very low birth weight infants for the prevention of staphylococcal infections have been added to the Bacterial Infections therapeutic trials section and to the overview section
  • 10 Apr 2006 Final results from a phase II clinical trial in very low birth weight infants for the prevention of staphylococcal infections have been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 03 Apr 2006 Interim results from a phase III clinical trial in premature infants for the prevention of nosocomial bloodstream infections due to S. aureus have been added to the adverse events and Bacterial Infections therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top